CASynergy: A causal attention model for interpretable prediction of cancer drug synergy
PLOS Computational Biology · 2025
DOI: 10.1371/journal.pcbi.1013567 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS Computational Biology, 2025. Verfasst von Haitao Li und 6 weiteren Autor:innen. Beteiligte Einrichtung: Key Laboratory of Intelligent Computing & Signal Processing, School of Artificial Intelligence, Anhui University, Hefei, Anhui, China. Hauptthemen laut MEDLINE: Neoplasms, Drug Synergism, Antineoplastic Agents. Die Arbeit nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: The University Synergy Innovation Program of Anhui Prov-ince, National Natural Science Foundation of China, Anhui Provincial Natural Science Foundation.
Abstract (Originalsprache)
Cancer drug combination therapies offer a promising strategy to overcome resistance and improve treatment efficacy, but identifying synergistic drug pairs is challenging due to complex biological interactions and tumor heterogeneity. Current machine learning algorithms for drug synergy prediction primarily rely on large-scale, multimodal datasets, yet suffer from critical limitations including poor interpretability, difficulty distinguishing causative biological relationships from correlations, and inadequate modeling of cancer-specific molecular interactions. To address these challenges, we propose CASynergy (Causal Attention and Cross-attention Synergy), a novel deep learning model for predicting cancer drug synergy that addresses limitations of prior approaches in accuracy and interpretability. CASynergy introduces a causal attention mechanism to distinguish true causal genomic features from spurious correlations, cell line-specific gene network construction to capture the unique molecular context of each cancer cell line, and a cross-attention module to integrate drug molecular features with cell line gene expression profiles. These improvements allow CASynergy to clearly identify significant drug-gene interactions and provides interpretable insights into why a combination is predicted to be synergistic. Experiments on two benchmark datasets (DrugCombDB and Oncology-Screen) suggests that CASynergy outperformed five state-of-the-art models. CASynergy offers a better and more reliable way to predict effective drug combinations. It works well across different cancer types and is easier to understand, which is important for personalized cancer treatment and finding new drugs.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Key Laboratory of Intelligent Computing & Signal Processing, School of Artificial Intelligence, Anhui University, Hefei, Anhui, China.
- Institute of Artificial Intelligence, Hefei Comprehensive National Science Center, Hefei, Anhui, China.
- School of Internet, Anhui University, Hefei, China.
Förderung
- The University Synergy Innovation Program of Anhui Prov-ince
- National Natural Science Foundation of China
- Anhui Provincial Natural Science Foundation
- The University Outstanding Youth Re-search Project of Anhui Province
- The University Synergy Innovation Program of Anhui Province
- Science Fund for Distinguished Young Scholars of Anhui Province
- The University Outstanding Youth Research Project of Anhui Province
- The Project of Key Laboratory of Intelligent Computing & Signal Processing (Anhui University), Ministry of Education
Zitieren
APA
Li, H., Zheng, L., Li, L., Chen, Y., Li, J., Zheng, C., & Su, Y. (2025). CASynergy: A causal attention model for interpretable prediction of cancer drug synergy. PLOS Computational Biology. https://doi.org/10.1371/journal.pcbi.1013567
Vancouver
Li H, Zheng L, Li L, Chen Y, Li J, Zheng C, et al. CASynergy: A causal attention model for interpretable prediction of cancer drug synergy. PLOS Computational Biology. 2025. doi:10.1371/journal.pcbi.1013567
BibTeX
@article{Li2025,
author = {Li, Haitao and Zheng, Long and Li, Lei and Chen, Yiwei and Li, Junjie and Zheng, Chunhou and Su, Yansen},
title = {CASynergy: A causal attention model for interpretable prediction of cancer drug synergy},
journal = {PLOS Computational Biology},
year = {2025},
doi = {10.1371/journal.pcbi.1013567}
}
EUVIMED